Over the past 20 years, significant progress has been achieved in the treatment of HER2-positive BC, and the U.S. Food and Drug Administration (FDA) has approved 7 kinds of HER2-targeted therapies for the treatment of early and/or advanced disease11. The gene discussed is ERBB2; the disease is breast cancer.